Key points from article :
Terray Therapeutics has secured an equity investment from NVentures, NVIDIA’s venture capital division, with additional support from renowned investors such as John Maraganore, founding CEO of Alnylam Pharmaceuticals, and Bassil Dahiyat, CEO of Xencor. This funding aims to enhance Terray’s generative AI capabilities for drug discovery.
The collaboration focuses on leveraging Terray’s extensive experimental data and NVIDIA’s advanced AI technologies to train comprehensive chemistry foundation models. These models are designed to optimize small molecule discovery, a crucial step in creating effective medicines. Terray will utilize NVIDIA DGX Cloud and BioNeMo services to develop scalable AI-driven models, combining computational power with high-throughput chemical experimentation.
Jacob Berlin, CEO of Terray Therapeutics, emphasized the unique scale and precision of Terray’s data, highlighting its ability to power AI-driven solutions for complex therapeutic challenges. The integration of NVIDIA’s state-of-the-art technology and Terray’s experimental data positions the partnership to accelerate the development of preclinical drug pipelines.
This initiative underscores the transformative potential of combining artificial intelligence and biotechnology. By tapping into NVIDIA’s computing expertise, Terray aims to streamline the process of discovering and optimizing drug candidates. The partnership represents a significant step toward advancing drug discovery, making it faster, more efficient, and cost-effective.
Terray’s innovative approach integrates data, AI, and chemical experimentation to address some of the toughest challenges in medicine development. This collaboration with NVIDIA is expected to pave the way for new breakthroughs, providing hope for quicker and more precise treatments for various diseases.
